Nov 11, 2025 • GlobeNewswire
NEUTRAL
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
BRISBANE, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at ...
Nov 11, 2025 • Benzinga
NEUTRAL
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business - Pacira BioSciences ( NASDAQ:PCRX )
DOMA Controls 6.8% of Pacira Common Stock MIAMI, Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. ( NASDAQ: PCRX ) ( "Pacira" ) , today sent a letter to the Board of Directors of Pacira ( the "Board" ) urging the Board to ...
Nov 04, 2025 • Benzinga
SOMEWHAT-BULLISH
AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera's long-acting non-opioid anesthetic for post-operative pain
Oct 27, 2025 • Benzinga
NEUTRAL
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical ( Hainan ) Co., Ltd. for EXPAREL® - Pacira BioSciences ( NASDAQ:PCRX )
BRISBANE, Calif., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( NASDAQ:PCRX ) , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter ( ...
Oct 27, 2025 • GlobeNewswire
NEUTRAL
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical ( Hainan ) Co., Ltd. for EXPAREL®
BRISBANE, Calif., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients today reported it has received a Paragraph IV Certification Notice Letter ( ...
Oct 23, 2025 • GlobeNewswire
NEUTRAL
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( NASDAQ: PCRX ) , the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world ...